Pancreatic cancer hENT1 expression and survival from Gemcitabine in patients from the ESPAC-3 trial.
Greenhalf, W Ghaneh, P Neoptolemos, J Palmer, D Cox, T Lamb, R Garner, E Campbell, F Mackey, J Costello, E
Greenhalf, W
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Lamb, R
Garner, E
Campbell, F
Mackey, J
Costello, E
Citations
Altmetric:
Abstract
Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection.
Authors
Greenhalf, W
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Lamb, R
Garner, E
Campbell, F
Mackey, J
Costello, E
Moore, M
Valle, Juan W
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Lacaine, F
Scarfe, A
Middleton, M
Anthoney, A
Halloran, C
Mayerle, J
Oláh, A
Jackson, R
Rawcliffe, C
Scarpa, A
Bassi, C
Büchler, M
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Lamb, R
Garner, E
Campbell, F
Mackey, J
Costello, E
Moore, M
Valle, Juan W
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Lacaine, F
Scarfe, A
Middleton, M
Anthoney, A
Halloran, C
Mayerle, J
Oláh, A
Jackson, R
Rawcliffe, C
Scarpa, A
Bassi, C
Büchler, M
Affiliation
Description
Date
2013-12-03
Publisher
Collections
Keywords
Type
Article
Citation
Pancreatic cancer hENT1 expression and survival from Gemcitabine in patients from the ESPAC-3 trial. 2013: J Natl Cancer Inst